Monitor EASL presentations (May 27-30) for actual 48-week efficacy data and fibrosis regression details. Positive selection for Best of EASL suggests data may be strong, but no quantitative results released yet. Watch for partnership interest or financing needs given $598M market cap and ongoing Phase 2 trials.
Price Chart
Executive Summary
Altimmune announced that its 48-week IMPACT Phase 2b data for pemvidutide in MASH has been selected for 'Best of EASL 2026' and will be presented at the EASL Congress in May 2026. The oral presentation will feature 48-week efficacy/safety results, while a late-breaker poster will show new digital pathology analysis of fibrosis regression at 24 weeks. This is a positive scientific validation event but does not provide new numerical data or regulatory milestones.
Key Facts
- 48-week IMPACT Phase 2b data selected for 'Best of EASL 2026' by EASL
- Oral presentation at EASL Congress May 27-30, 2026 in Barcelona
- Late-breaker poster on digital pathology analysis of fibrosis regression at 24 weeks
- Pemvidutide has FDA Fast Track for MASH and AUD, Breakthrough Therapy for MASH
- RECLAIM (AUD) and RESTORE (ALD) Phase 2 trials ongoing since May/July 2025
- IMPACT trial enrolled 212 patients with biopsy-confirmed MASH F2/F3
Financial Impact
No financial figures disclosed; scientific validation event with potential to de-risk Phase 3 program
Risk Factors
- No new numerical data released yet; market may have already priced in positive expectations
- Competition from other MASH therapies (e.g., Rezdiffra, semaglutide) could limit commercial potential
- Cash burn from ongoing trials without near-term revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293871 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $2.97 $2.67 | ▼ −10.10% | ▼ −12.05% | $2.09 (−29.63%) |
Aug 12, 2026 10w ago | 8-K | $2.93 $3.12 | ▲ +6.48% | ▲ +6.93% | $2.09 (−28.67%) |
Aug 12, 2026 10w ago | Press Release | $2.93 $3.12 | ▲ +6.48% | ▲ +6.93% | $2.09 (−28.67%) |
Aug 6, 2026 11w ago | Institutional Cluster | $3.01 $2.88 | ▼ −4.32% | ▼ −5.53% | $2.09 (−30.56%) |
Aug 5, 2026 11w ago | Press Release | $3.03 $2.93 | ▼ −3.30% | ▼ −3.65% | $2.09 (−31.02%) |
Aug 3, 2026 12w ago | Press Release | $3.00 $3.05 | ▲ +1.67% | ▼ −0.36% | $2.09 (−30.33%) |
Jul 28, 2026 12w ago | 8-K | $2.99 $3.00 | ▲ +0.33% | ▼ −1.93% | $2.09 (−30.10%) |
May 28, 2026 21w ago | Press Release | $3.07 $2.87 | ▼ −6.51% | ▼ −6.47% | $2.09 (−31.92%) |
May 27, 2026 21w ago | Press Release | $2.98 $2.90 | ▼ −2.68% | ▼ −3.89% | $2.09 (−29.87%) |
May 13, 2026 23w ago | 8-K | $3.02 $2.74 | ▼ −9.27% | ▼ −8.11% | $2.09 (−30.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers